Human pathology

Home page > E. Pathology by systems > Endocrine system > Thyroid > thyroid papillary carcinoma

thyroid papillary carcinoma

TPC

Clinical synops

- 5-20% have local recurrences
- 10-15% distant metastases (lung, bones, CNS)is
- women of reproductive age (70%)
- 90% of childhood thyroid malignancies are papillary
- 6% Occult tumorsat autopsy (1 to 10 mm)
- 46% multicentric
- 14% with nodal metastases
- Occult tumors in up to 24% with other thyroid disease, surprisingly with male predominance
- painless nodule
- mass in neck or cervical node

  • 67% in thyroid only, 13% in thyroid and cervical nodes, 20% in nodes only

Risk factors

- ionizing radiation before age 20 (for acne, tonsillitis, tinea capitis)
- post-Chernobyl or nuclear explosions at Marshall Islands
- Hashimoto thyroiditis
- Gardner syndrome with germline APC mutations
- multiple hamartomas syndrome (Cowden syndrome)

Prognosis

- 10 year survival:

  • 98%, similar to general population
  • 100% if under age 20, even with nodal metastases

- Cervical node involvement does not affect the prognosis.
- Poorer prognosis:

  • age 40+ or elderly
  • male
  • local invasion
  • distant metastases (bone worse than lung)
  • large tumor size
  • tall cell/columnar variant
  • diffuse sclerosing variant
  • exposure to radiation
  • lymphatic invasion

Synopsis

- Gross: solid, white, firm, often multifocal (20%), encapsulated (10%) or infiltrative; variable cysts, fibrosis, calcification
- complex, branching papillae with fibrovascular cores associated with follicles
- nuclei are overlapping with finely dispersed optically clear chromatin (also called ground-glass, Orphan-Annie nuclei, not seen in cytology or frozen section material)
- micronucleoli
- eosinophilic intranuclear inclusions (cytoplasmic invaginations)
- nuclear longitudinal grooves (folding of redundant nuclear membrane)
- psammoma bodies

  • present in 50% in papillary stalk in fibrous stroma between tumor cells;
  • +/- specific for papillary carcinoma

- +/- vascular invasion (5%)
- +/- dense fibrosis
- +/- squamous metaplasia
- +/- solid areas
- +/- inflammatory cells: lymphocytes, histiocytes, histiocytic multinucleate giant cells, Langerhans cells
- +/- spindle cell metaplasia
- +/- mitotic figures
- +/- mucinous metaplasia

Differential diagnosis

- lymphocytic thyroiditis with reactive nuclear changes

  • nuclei are still round, no inclusions
  • background of lymphocytes and plasma cells without fibrosis

- hyperplastic ultimobranchial body rests / solid cell nests

  • in lateral lobes
  • round to oval structures
  • +/- chromatin clearing or grooves
  • central cysts
  • mucin
  • squamous metaplasia
  • cytokeratin strongly positive, thyroglobulin negative

- papillary foci of Graves’disease

  • strong p27 staining vs. weak in papillary carcinoma

- tumoral metastases

Variants

- columnar TPC
- cribriform-morular TPC
- diffuse sclerosing TPC
- follicular TPC
- encapsulated TPC
- encapsulated follicular TPC
- Hashimoto thyroiditis TPC
- macrofollicular TPC
- microcarcinoma TPC
- nodular fasciitis like stroma TPC
- oncocytic TPC
- solid TPC
- tall cell TPC
- Warthin-like TPC
- well differentiated TPC

Predisposition

- familial papillary thyroid carcinoma (FPTC)
- familial adenomatous polyposis (FAP) (16400511, 15256777, 7698732)

Chromosomal comparative genomic hybridization (CGH)

- low prevalence of aberrations
- majority of tumors showing no evidence of chromosomal instability

- gains: chromosomes 1, 5, 7, 11, 15, 17, and 22

- losses: chromosomes 4, 18, and 19

Regional amplification

- TP73 (1p36 amplification)
- SNRPN (15q12 amplification)
- PDGFB (22q13 amplification)

Gene mutations

Oncogenic activation of BRAF (35% to 69%), RAS (10%), or RET (5% to 30%) is common in PTC, and the mutations correlate with tumor subtype, patient age, and clinical behavior.

- BRAF mutations (35% to 69%) (17199440)
- RAS mutations (10%)
- RET mutations (5% to 30%)

See also

- ovarian papillary thyroid carcinoma (malignant struma ovarii).

References

- Finn S, Smyth P, O’Regan E, Cahill S, Toner M, Timon C, Flavin R, O’Leary J, Sheils O. Low-level genomic instability is a feature of papillary thyroid carcinoma: an array comparative genomic hybridization study of laser capture microdissected papillary thyroid carcinoma tumors and clonal cell lines. Arch Pathol Lab Med. 2007 Jan;131(1):65-73. PMID: 17227125

- McCarthy RP, Wang M, Jones TD, Strate RW, Cheng L. Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas. Clin Cancer Res. 2006 Apr 15;12(8):2414-8. PMID: 16638846